Claroid Pharmaceuticals Files DRHP With Sebi For IPO To Fund ₹168-Crore Ahmedabad Manufacturing Facility

New Delhi, September 23 -- Pharmaceutical company Claroid Pharmaceuticals has submitted draft prospectus documents to the Securities and Exchange Board of India (Sebi) for an initial public offering (IPO). The company plans to raise up to ₹1,689 crore through the sale of 74.5 lakh equity shares and an offer for sale of 51.5 lakh shares, totaling 1.26 crore shares.

The funds will be utilized to finance the construction of a new manufacturing facility in Ahmedabad at the company's existing land. The proposed plant will produce injectables, ampoules, vials, dry powder, pre-filled syringes, and eye-drop products, with an estimated cost of ₹167.97 crore and a monthly production capacity of 15 lakh units.

Claroid Pharmaceuticals currently operates a facility in Pirana, Ahmedabad, where it manufactures tablets, capsules, and ointments. The company has developed 129 pharmaceutical formulations across various therapeutic segments, such as anti-infective, anti-inflammatory, anti-fungal, dermatology, pain management, and gastrointestinal therapies.

In recent years, the company has experienced significant revenue growth, with operations reaching ₹169.72 crore in FY26 compared to ₹62.98 crore in FY24, a compound annual growth rate (CAGR) of 64.13%. Claroid Pharmaceuticals holds GMP certifications from regulatory authorities in Rwanda, Ghana, Tanzania, and Zanzibar, and maintains an export presence in several African countries, including Nigeria, Tanzania, Kenya, Myanmar, Zanzibar, and Botswana, with Nigeria being its largest export market.

The company boasts an in-house formulation and development facility along with quality control, quality assurance, and microbiology laboratories, supported by over 30 distributors across Africa. The IPO is being organized by Oneview Corporate Advisors and Valmiki Leela Capital as the book-running lead managers.